Product Images Gabapentin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 12 images provide visual information about the product associated with Gabapentin NDC 44523-120 by Biocomp Pharma, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - Figure 1

Figure 1 - Figure 1

label - Figure 2

label - Figure 2

label - Figure 3

label - Figure 3

label - Formula 1

label - Formula 1

label - Table 1

label - Table 1

Renal Function Total Daily Dose Regimen (mg): - For individuals with renal clearance greater than 60 mL/min, the total daily dose regimen ranges from 900 mg to 3600 mg. Options for three times a day (TID) dosing include 300 mg, 400 mg, 600 mg, 800 mg, and 1200 mg. - For individuals with renal clearance between 30 and 59 mL/min, the total daily dose regimen ranges from 400 mg to 1400 mg. Options for twice a day (BID) dosing include 200 mg, 300 mg, 400 mg, 500 mg, and 700 mg. - For individuals with renal clearance between 15 and 29 mL/min, the total daily dose regimen ranges from 200 mg to 700 mg. Options for once a day (QD) dosing include 200 mg, 300 mg, 400 mg, 500 mg, and 700 mg. - For individuals with renal clearance of 15 mL/min or lower, the total daily dose regimen ranges from 100 mg to 300 mg. Options for daily (D) dosing include 100 mg, 125 mg, 150 mg, 200 mg, and 300 mg. Post-Hemodialysis Supplemental Dose (mg): - For individuals undergoing hemodialysis, the supplemental dose options are 125 mg, 150 mg, 200 mg, 250 mg, and 350 mg.*

label - Table 3

label - Table 3

Not available.*

label - Table 4

label - Table 4

label - Table 5

label - Table 5

Gabapentin is a medication that is commonly used to treat various conditions such as epilepsy and neuropathic pain. This evaluation provides a comparison between the effects of Gabapentin and a placebo in a study involving 119 participants for Gabapentin and 128 participants for Placebo. The evaluation shows the percentage of participants who experienced different side effects in different body systems. For example, in the body as a whole, 1% of participants on Gabapentin experienced viral infection compared to 3% on Placebo. Other reported side effects include fever, increased weight, fatigue, nausea and/or vomiting, somnolence, hostility, emotional lability, dizziness, hyperkinesia, bronchitis, and respiratory infection. These results provide useful information for medical professionals and patients considering the use of Gabapentin.*

Chemical structure - image 02

Chemical structure - image 02

Figure 4 - image 06

Figure 4 - image 06

label - label

label - label

label - logo 1

label - logo 1

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.